pCPAO
For a more in-depth look at market access trends and timelines comparing 2021 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. Please contact info@morseconsulting.ca regarding any questions on this infographic or on the CRaFT report. Embed this infographic (copy and paste code) on your website with attribution: <p><a href="https://morseconsulting.ca/morse-consulting-releases-its-pcpa-quarterly-update-q4-2022"><img…
MORSE has been providing monthly data analytics and expert insights through our pCPA updates since 2017. Starting in 2022, MORSE is now publishing the pCPA updates on a quarterly basis. For a more in-depth look at market access trends and timelines comparing 2021 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size…
Toronto, September 7, 2022 – MORSE Consulting is delighted to announce the addition of 2 new team members, Jaclyn Beca and Sang Mi Lee who will enhance MORSE’s reimbursement expertise into pharmacoeconomics, generation and use of real world evidence (RWE) and development of innovative agreements. We are at an exciting time in drug discovery and research as new technologies, such as cell and gene therapies, offer opportunities to treat and…
MORSE has been providing monthly data analytics and expert insights through our pCPA updates since 2017. Starting in 2022, MORSE is now publishing the pCPA updates on a quarterly basis. Last quarter, Keytruda initiated and completed pCPA negotiations 2022-02-11. This was not captured in our previous update, but has since been accounted for in our dataset and the infographic below. For a more in-depth look at market access trends and…
MORSE has been providing data analytics and expert insights through our pCPA updates on a monthly basis since 2017. Starting in 2022, MORSE will be publishing the pCPA updates quarterly instead of monthly. We extend our gratitude to those who provided feedback in anticipation for the transition to a quarterly update. We are pleased to release our first Quarterly pCPA Update Infographic. This resource is aimed at helping market access…
Recently announced changes to CADTH’s Reimbursement Review submission requirements, effective October 2022 necessitates completion of the Sponsor Summary of Clinical Evidence template. The new clinical evidence template is comprehensive, including but not limited to: background information on the clinical condition, current treatment paradigm, unmet need, and place in therapy methods and findings of a systematic literature search for clinical trials of the drug under review summary of evidence from other…
MORSE Consulting is pleased to release our Fifth Annual pCPA Year in Review Infographic – 2021 Edition. This resource is aimed at helping market access stakeholders understand the top-line pCPA highlights from 2021. This infographic compares year-over-year metrics including: pCPA activity summary; addresses backlog of files under consideration; average time to complete a negotiation; and files adjudicated by the pCPA by type. MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT)…
pan-Canadian Pharmaceutical Alliance (pCPA): December 2021 Trends and Insights UPDATE & REQUEST FOR PARTICIPATION IN A SURVEY MORSE has been providing data analytics and expert insights through our pCPA updates on a monthly basis since 2017. Starting in 2022, MORSE will be publishing the pCPA updates quarterly instead of monthly. By analyzing quarterly vs. monthly data we expect to be able to identify important trends and provide useful insights…
pan-Canadian Pharmaceutical Alliance (pCPA): November 2021 Trends and Insights November 2021 Highlights: 3 products completed CADTH review 15 products initiated pCPA negotiations 3 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Key Take-Aways: The number of files under consideration was reduced substantially from 31 in October to 22 as of November 30th, driven by relatively few CADTH…
pan-Canadian Pharmaceutical Alliance (pCPA): October 2021 Trends and Insights October 2021 Highlights: 3 products completed CADTH review 6 products initiated pCPA negotiations 8 negotiations were completed with an LOI 0 negotiation were closed without an LOI 0 file were closed without negotiation Key Take-Aways: The volume of files under consideration has decreased steadily over the past three months from 37 in August to 31 as of October 31st.…
pan-Canadian Pharmaceutical Alliance (pCPA): September 2021 Trends and Insights September 2021 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 7 negotiations were completed with an LOI 1 negotiation was closed without an LOI 1 file was closed without negotiation Key Take-Aways: The number of files under consideration at pCPA decreased slightly to 34 from last month’s high, while the average days under consideration had a…
pan-Canadian Pharmaceutical Alliance (pCPA): August 2021 Trends and Insights August 2021 Highlights: 8 products completed CADTH review 4 products initiated pCPA negotiations 10 negotiations were completed with an LOI No negotiations were closed without an LOI No files were closed without negotiation Key Take-Aways: The output of the pCPA in August was a high number of completed negotiations and slightly less files initiated for negotiations than usual. Partly…
Toronto, September 7, 2021 – MORSE Consulting is pleased to announce the addition of Katherine Scott as a Consultant. The Canadian public system remains one of the critical payers in this country’s pharmaceutical reimbursement pathway. This system is growing increasingly complex with new funding mechanisms for emerging gene and cell therapies, novel approaches related to outcomes-based agreements, evolving policies related to biosimilars, and variations in how provincial payers implement pCPA…
pan-Canadian Pharmaceutical Alliance (pCPA): July 2021 Trends and Insights July 2021 Highlights: 5 products completed CADTH review 5 products initiated pCPA negotiations 3 negotiations were completed with an LOI 1 negotiation was closed without an LOI 1 file was closed without negotiation Key Take-Aways: CADTH released no non-oncology recommendations in July. The volume of files under consideration remains relatively stable in July at 30, with no decrease in…
pan-Canadian Pharmaceutical Alliance (pCPA): June 2021 Trends and Insights June 2021 Highlights: 8 products completed CADTH review 12 products initiated pCPA negotiations 3 negotiations were completed with an LOI 0 negotiations were closed without an LOI 2 files were closed without negotiation Key Take-Aways: The volume of files under consideration remains stable with a slight decrease in the days under consideration in June relative to the last 6…
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
pCPAO - Info and details on - MORSE Consulting Inc.